Abbott and AstraZeneca have entered into an agreement under which the two companies will co-promote Abbott’s cholesterol drug Trilipix (fenofibric acid) in the U.S. Financial terms were not disclosed. “Abbott’s portfolio of lipid therapies is designed to help physicians manage a patient’s total lipid profile,” said Jeffrey Stewart, divisional vice president, Primary Care, Abbott. “With AstraZeneca’s established presence in the cardiovascular space, th...